Abstract:Abstract Among the prerequisites to be effective, immunotherapy must work in the presence of the host immunosuppression. Myeloid-derived suppressor cells (MDSCs) are one of the cellular mediators that have a role in limiting the induction of adaptive immune response and host responses to immunotherapy. MDSCs are an immature, heterogeneous cellular population, including hematopoietic precursors for granulocytes, macrophages, dendritic cells, and endothelial cells. They are infrequent in healthy hosts, but increase during tumor progression as a result of dysregulated myeloid cell expansion and differentiation. Tumor growth is frequently associated with an increased frequency of MDSCs that results in a loss in T-cell number and function through increased ROS and peroxynitrites production and arginase 1 (ARG1) and nitric oxide synthase 2 (NOS-2) upregulation. A better understanding of MDSCs expansion and the regulation of biodistribution and arrest would improve interventional strategies and cancer immunotherapy outcomes. Using five mammary tumor models, we have examined tumor-associated expansion of MDSCs and observed that this occurs in an organ-specific manner. Murine MDSCs can be subdivided into phenotypically and functionally distinct sub-populations according to Gr-1 expression levels; the CD11b+Gr-1 dim MDSCs with monocytic nuclei and strong T-cell suppressive activity, and CD11b+Gr-1bright having ring-shaped nuclei (polymorphonuclear cells) and a lower T-cell suppression profile. These cells can also be subset based on the expression of Ly-6C which is highly expressed on immature, bone marrow-derived cells and combined this Gr-1 expression Our studies revealed a significant increase in the Ly-6Cbright expression on the CD11b+Gr-1dim MDSCs in all organs studied in tumor-bearing mice as compared to non-tumor-bearing mice. In association with the increase in CD11b+Gr-1dimLy-6Cbright cells in the tumor non-parenchymal cells of 4T1 tumor bearing mice, increased transcripts levels of cytokines associated with MDSCs expansion (granulocyte-colony stimulating factor [G-CSF]) and MDSCs-associated immunosuppression (ARG-1, NOS-2, and cyclooxygenase 2 [COX-2]) while lower levels of these cytokines were observed in tumor NPCs from Cl66 tumor-bearing mice and non-tumor-bearing mice. In association with the increase in MDSCs and loss of T-cells in the 4T1 tumor-bearing mice there was a significant decrease in cytokine transcript levels that can enhance immune response (interferon gamma [IFN-γ] and interleukin 12 [IL-12]) from tumor non-parenchymal cells (NPCs) in 4T1 tumor bearing mice as compared to Cl66 tumor bearing mice and non-tumor bearing mice. Studies to assess where the MDSCs were expanding revealed that in 4T1 tumor bearing mice, frequency of the proliferating MDSCs is increased only in the spleen and liver compared to the non-tumor-bearing mice. Our studies also examined the affect of tumor burden on the trafficking of MDSCs. We observed that, after adoptive transfer of MDSCs isolated from 4T1 tumor-bearing mice, they arrest initially within the lungs in non-tumor-bearing mice. While in 4T1 tumor-bearing mice they rapidly transverse the lungs with arrest within the tumor tissue. We and others reported that the increase in MDSCs frequencies is associated with a decrease in CD3+ cells function and numbers. We observed a decrease in frequency of all T-cell subsets in the thymus of tumor bearing mice tested compared to the non-tumor-bearing mice suggesting defects in T-cell maturation associated with tumor burden. We investigated the effect of tumor burden on the phenotype of the CD3+ cells using the Annexin V staining and found that 4T1 tumor bearing mice have increased frequency of Annexin V positive CD3+ T-cells that are infiltrating tumor tissue compared to those in other organs. Citation Information: Clin Cancer Res 2010;16(14 Suppl):B52.

Abstract 5320: Deletion of TGFß signaling in Gr-1+CD11b+ myeloid cells attenuates breast adenocarcinoma progression

Abstract 1344: TGFß, an Inflammation and Immune Suppressor in Tumor Microenvironment and Progression

Gr-1+Cd11b+Cells Are Responsible For Tumor Promoting Effect Of Tgf-Ss In Breast Cancer Progression

Abstract 1435: Myeloid TGF-β Signaling Regulates Platelet Factor 4 Expression That is Important in Host Immune Suppression and Tumor Metastasis.

Abstract 3969: Stromal Depletion of Transforming Growth Factor Receptor 2 Promotes the Development of Forestomach Squamous Cell Carcinoma

TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis.

Gr-1+CD11b+ Myeloid Cells Tip the Balance of Immune Protection to Tumor Promotion in the Premetastatic Lung

Abstract 3172: CCL9 Induction in Myeloid Cells of the Premetastatic Niche Enhances Tumor Cell Survival and Metastatic Colonization

Abstract 50: Abrogation of Stromal TGF-β Signaling Induces DNA Damage and Genetic/epigenetic Alterations in Neighboring Epithelia

Abstract IA33: Regulation of TGF-β receptor signaling in cancer

Abstract B022: Tumoral GLI1 controls the resident innate and adaptive tumor immune microenvironment in triple negative breast cancer

The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects

Abstract 1105: Tumor Cells of the Early Metastatic Process Show Up Regulation of Cytokine Genes Involved in Migration of Inflammatory Cells

Abstract 3919: Targeting tissue-resident macrophage progenitors by anti-IL34 restores anti-tumor immunity and suppresses tumor growth

Abstract 2698: TCF-1 is a critical regulator of intraepithelial lymphocytes in colorectal carcinoma

Abstract B52: Characterizing the MDSCs phenotypes, expansion, and trafficking pattern and associated tumor-induced immune dysfunction

Abstract 105: Understanding the role of β2-adrenergic receptor signaling on type II innate lymphoid cells in cancer

[Abnormal granulocyte differentiation and the paradoxical switch of transforming growth factor-β1 in breast cancer patients]

Abstract B038: CD4Th1 cytokine interferon gamma regulates genome profiles and inhibits tumorigenesis of disseminated cancer cells in breast cancer

Abstract B023: Regulatory T (Treg) cell contributes to tumor cell dissemination via extracellular matrix (ECM) remodeling, which is driven by TAMs in an IFNg-dependent manner

Abstract 5308: Ifngr1 signaling on tumor-specific CD4 T cells is required to mitigate Treg differentiation during CD40 agonist and anti-PD-L1 immunotherapy in pancreatic ductal adenocarcinoma